High Park Farms Receives Cannabis Cultivation License From Health Canada

CANADA:  High Park Farms announced that it has received a federal license from Health Canada to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The High Park Farms facility, which is anticipated to represent an investment of up to $30 million, features 13 acres of greenhouse on 100 acres of property in Enniskillen, Ontario.

“This license is a major milestone for High Park as we work to prepare for the anticipated launch of the world’s largest federally legal cannabis market later this year,” said Adine Carter, Chief Marketing Officer of High Park.

High Park Farms will begin cultivating cannabis plants in its greenhouse next week and anticipates its first harvest in June. In accordance with the Cannabis Act introduced in Canadian parliament in April 2017, High Park Farms anticipates that its ACMPR cultivation license will provide the company the ability to supply the adult-use cannabis market in Canada once the legislation is adopted.

High Park launched earlier this month to produce and distribute a broad-based portfolio of cannabis brands and products for the Canadian market in anticipation of adult-use legalization. Based in Toronto and led by a team with deep experience in cannabis and global consumer brands, High Park has secured the exclusive rights to produce and distribute a broad-based portfolio of adult-use cannabis brands and products in Canada, subject to applicable laws and regulations. In addition, High Park has developed new brands and products for the Canadian market. Pending federal legalization of cannabis for adult-use and corresponding provincial legislation, High Park anticipates fulfilling adult-use supply agreements in QuebecManitoba, and Yukon. High Park plans to secure additional supply agreements with crown corporations and private entities in other provinces in the coming months.

Tokyo Smoke Partners With Aphria To Launch Medical Cannabis

CANADA: Tokyo Smoke introduces four medical cannabis strains in collaboration with Aphria, one of Canada’s largest licensed producers of medical marijuana. This is the first time a Canadian consumer brand will partner with a Licensed Producer to launch medical cannabis in Canada, an inaugural event for the lifestyle brand, as well as the Canadian marketplace. Grown and distributed by Aphria under the ACMPR (Access to Cannabis for Medical Purposes Regulations), the cannabis strains will be available to patients with a valid medical prescription from August 24, 2017.

The four strains will launch as a part of a kit ($250), featuring unique Tokyo Smoke packaging, five grams of each strain along with custom crafted black glass jars and special welcome accessories. They will be available to order through the Aphria website.

“This launch is the culmination of Tokyo Smoke’s vision of providing a beautiful cannabis experience in both design and product,” says Alan Gertner, co-founder and CEO of Tokyo Smoke. “When conceptualizing each strain, we wanted to pair consistent, high-quality cannabis with a focus on Tokyo Smoke branding, design and packaging. Contemporary customers deserve to have a cannabis experience that aligns with the rest of their lifestyle.”